These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


436 related items for PubMed ID: 19361440

  • 1. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains.
    Williams NK, Bamert RS, Patel O, Wang C, Walden PM, Wilks AF, Fantino E, Rossjohn J, Lucet IS.
    J Mol Biol; 2009 Mar 20; 387(1):219-32. PubMed ID: 19361440
    [Abstract] [Full Text] [Related]

  • 2. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6.
    Chrencik JE, Patny A, Leung IK, Korniski B, Emmons TL, Hall T, Weinberg RA, Gormley JA, Williams JM, Day JE, Hirsch JL, Kiefer JR, Leone JW, Fischer HD, Sommers CD, Huang HC, Jacobsen EJ, Tenbrink RE, Tomasselli AG, Benson TE.
    J Mol Biol; 2010 Jul 16; 400(3):413-33. PubMed ID: 20478313
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of Janus kinases by tyrosine phosphorylation inhibitor, Tyrphostin AG-490.
    Rashid S, Bibi N, Parveen Z, Shafique S.
    J Biomol Struct Dyn; 2015 Jul 16; 33(11):2368-79. PubMed ID: 26017266
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Advances in the discovery of selective JAK inhibitors.
    Menet CJ, Rompaey LV, Geney R.
    Prog Med Chem; 2013 Jul 16; 52():153-223. PubMed ID: 23384668
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R.
    Pharmacol Res; 2016 Sep 16; 111():784-803. PubMed ID: 27473820
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Expression, purification, characterization and crystallization of non- and phosphorylated states of JAK2 and JAK3 kinase domain.
    Hall T, Emmons TL, Chrencik JE, Gormley JA, Weinberg RA, Leone JW, Hirsch JL, Saabye MJ, Schindler JF, Day JE, Williams JM, Kiefer JR, Lightle SA, Harris MS, Guru S, Fischer HD, Tomasselli AG.
    Protein Expr Purif; 2010 Jan 16; 69(1):54-63. PubMed ID: 19781647
    [Abstract] [Full Text] [Related]

  • 12. Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.
    Constantinescu SN, Leroy E, Gryshkova V, Pecquet C, Dusa A.
    Biochem Soc Trans; 2013 Aug 16; 41(4):1048-54. PubMed ID: 23863177
    [Abstract] [Full Text] [Related]

  • 13. JAK pathway induction of c-Myc critical to IL-5 stimulation of cell proliferation and inhibition of apoptosis.
    Lee WH, Liu FH, Lin JY, Huang SY, Lin H, Liao WJ, Huang HM.
    J Cell Biochem; 2009 Apr 01; 106(5):929-36. PubMed ID: 19180571
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.
    Kulagowski JJ, Blair W, Bull RJ, Chang C, Deshmukh G, Dyke HJ, Eigenbrot C, Ghilardi N, Gibbons P, Harrison TK, Hewitt PR, Liimatta M, Hurley CA, Johnson A, Johnson T, Kenny JR, Bir Kohli P, Maxey RJ, Mendonca R, Mortara K, Murray J, Narukulla R, Shia S, Steffek M, Ubhayakar S, Ultsch M, van Abbema A, Ward SI, Waszkowycz B, Zak M.
    J Med Chem; 2012 Jun 28; 55(12):5901-21. PubMed ID: 22591402
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 22.